文献速递胸部肿瘤

D-1553(格索拉西布)作为KRAS G12C强效选择性抑制剂治疗非小细胞肺癌患者的1期研究结果

D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results.
PubMed 文献 · J Thorac Oncol · 2023-03-21

本研究在中国多中心开展1期剂量递增和剂量扩展试验,评估口服KRAS G12C抑制剂D-1553(格索拉西布)治疗KRAS G12C突变非小细胞肺癌。79例可评估安全性患者中94.9%报告治疗相关不良事件,38.0%发生3或4级事件;74例可评估疗效患者确认客观缓解率为40.5%,疾病控制率为91.9%,中位无进展生存期8.2个月,中位缓解持续时间7.1个月。

要点

  • 79例接受治疗患者中94.9%报告治疗相关不良事件,38.0%发生3或4级事件,多数不良事件可控。
  • 74例可评估疗效患者确认客观缓解率40.5%,疾病控制率91.9%,中位无进展生存期8.2个月。
  • 推荐2期剂量下62例可评估患者客观缓解率38.7%,疾病控制率90.3%,中位无进展生存期7.6个月。

核心结论

  • D-1553(格索拉西布)对KRAS G12C突变非小细胞肺癌患者显示出良好耐受的安全性和令人鼓舞的抗肿瘤活性,有望成为治疗选择。

研究设计与样本

  • 在中国多中心开展的1期剂量递增和剂量扩展研究,评估D-1553的安全性、药代动力学和疗效。
  • 剂量递增阶段给药方案包括600 mg每日一次、800 mg每日一次、1200 mg每日一次、400 mg每日两次或600 mg每日两次口服;剂量扩展阶段所有患者接受600 mg每日两次。
  • 共79例患者接受治疗纳入安全性分析,74例可评估疗效分析,62例在推荐2期剂量下可评估缓解。

主要发现

  • 79例接受治疗患者中75例(94.9%)报告治疗相关不良事件,30例(38.0%)发生3或4级事件,多数不良事件可控且患者耐受良好。
  • 74例可评估疗效患者中30例达部分缓解、38例疾病稳定,确认客观缓解率40.5%,疾病控制率91.9%,中位无进展生存期8.2个月,中位缓解持续时间7.1个月。
  • 推荐2期剂量下62例可评估患者中24例(38.7%)达部分缓解、32例(90.3%)疾病稳定,中位无进展生存期7.6个月,中位缓解持续时间6.9个月。
  • 脑转移患者中客观缓解率为17%,疾病控制率为100%。

关键数值与推荐

  • 74例可评估疗效患者确认客观缓解率40.5%,疾病控制率91.9%。
  • 推荐2期剂量下62例可评估患者客观缓解率38.7%,疾病控制率90.3%。
  • 脑转移患者客观缓解率17%,疾病控制率100%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: D-1553 (garsorasib) is a potent and selective oral KRASG12C inhibitor. We report results from a phase I dose-escalation and dose-expansion study of D-1553 in patients with KRAS G12C-mutated NSCLC in multiple sites in the People's Republic of China. METHODS: Patients with KRAS G12C-mutated NSCLC have administrated D-1553 600 mg orally once daily, 800 mg once daily, 1200 mg once daily, 400 mg twice a day, or 600 mg twice a day in dose escalation. In dose-expansion, all patients received 600 mg twice a day. The safety, pharmacokinetics, and efficacy of D-1553 were evaluated. RESULTS: Among a total of 79 treated patients, 75 patients (94.9%) reported treatment-related adverse events with 30 patients experiencing grade 3 or 4 events (38.0%). Most of the adverse events were manageable and the patients tolerated the study treatment well. Among 74 patients assessable for efficacy analysis, 30 patients had a partial response and 38 had stable disease with a confirmed objective response rate (ORR) and disease control rate (DCR) of 40.5% and 91.9%, respectively. The median progression-free survival was 8.2 months, and the median duration of response was 7.1 months. Among 62 patients assessable for response at the recommended phase 2 dose, partial response occurred in 24 patients (ORR, 38.7%) and stable disease in 32 patients (DCR, 90.3%). The median progression-free survival and duration of response were 7.6 months and 6.9 months, respectively. In patients with brain metastasis, ORR and DCR were 17% and 100%, respectively. CONCLUSIONS: D-1553 represents a promising therapeutic option for patients with KRAS G12C-mutated NSCLC with a well-tolerated safety profile and encouraging antitumor activity.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Li Z, Song Z, Zhao Y, et al. D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results. J Thorac Oncol. 2023. PMID: 36948246. doi:10.1016/j.jtho.2023.03.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。